Duan Jingwei, Pogue Joel A, Boggs Drexell H, Harms Joseph
Radiation Oncology, University of Alabama at Birmingham, Birmingham, USA.
Cureus. 2024 Aug 15;16(8):e66943. doi: 10.7759/cureus.66943. eCollection 2024 Aug.
This study explores the dosimetric benefits of cone-beam computed tomography (CBCT)-based online adaptive radiation therapy (oART) for a non-small-cell lung cancer (NSCLC) patient exhibiting significant tumor shrinkage during ChemoRT. The patient was prescribed 60 Gray (Gy) in 30 fractions and was initially treated with conventional RT. After the delivery of the first four treatment fractions, the patient's treatment course was converted to oART due to tumor shrinkage seen on CBCT. Current oART dose calculations use a synthetic CT (sCT) image derived from deformable image registration (DIR) of the planning CT to the daily CBCT, and, as the tumor regressed, the discrepancy between the CBCT and the sCT increased, leading to a re-simulation after the delivery of the ninth fraction. In this case report, we first investigated dosimetric differences leveraged by converting this patient from conventional RT to oART. With oART using sCT, the patient's target coverage remained consistent with the reference plan while simultaneously changing lung V20 by 7.8 ± 1.4% and heart mean by 3.4 ± 1.5 Gy. Then, using this new simulation CT and comparing it with iterative CBCT (iCBCT) images acquired with the new HyperSight™ (HS) (Varian Medical Systems, Inc., Palo Alto, CA, USA) imaging system on the Ethos, we investigated the impact of direct dose calculation on HS-iCBCT as compared to sCT. The HS-iCBCT generated a dose distribution similar to the CT reference, achieving a 96.01% gamma passing rate using Task Group-218 (TG-218) criteria. Results indicate that HS-iCBCT has the potential to better reflect daily anatomical changes, resulting in improved dosimetric accuracy. This study highlights the advantages of oART in the presence of tumor response to therapy and underscores HS-iCBCT's potential to provide CT-level dose calculation accuracy in oART for NSCLC patients.
本研究探讨了基于锥束计算机断层扫描(CBCT)的在线自适应放射治疗(oART)对一名在放化疗期间肿瘤显著缩小的非小细胞肺癌(NSCLC)患者的剂量学益处。该患者被处方60格雷(Gy),分30次给予,最初接受传统放疗。在给予前四个治疗分次后,由于CBCT上显示肿瘤缩小,患者的治疗疗程转换为oART。当前的oART剂量计算使用从计划CT到每日CBCT的可变形图像配准(DIR)得出的合成CT(sCT)图像,并且随着肿瘤退缩,CBCT与sCT之间的差异增加,导致在给予第九个分次后进行重新模拟。在本病例报告中,我们首先研究了将该患者从传统放疗转换为oART所利用的剂量学差异。使用sCT的oART使患者的靶区覆盖与参考计划保持一致,同时肺V20改变了7.8±1.4%,心脏平均剂量改变了3.4±1.5 Gy。然后,使用这个新的模拟CT并将其与在Ethos上使用新型HyperSight™(HS)(美国瓦里安医疗系统公司,加利福尼亚州帕洛阿尔托)成像系统获取的迭代CBCT(iCBCT)图像进行比较,我们研究了与sCT相比直接在HS-iCBCT上进行剂量计算的影响。HS-iCBCT生成的剂量分布与CT参考相似,使用任务组218(TG-218)标准达到了96.01%的伽马通过率。结果表明,HS-iCBCT有潜力更好地反映每日解剖学变化,从而提高剂量学准确性。本研究突出了oART在存在肿瘤对治疗反应时的优势,并强调了HS-iCBCT在NSCLC患者的oART中提供CT级剂量计算准确性的潜力。